News

November 19, 2020November 19, 2020

Dana-Farber Scientist Awarded $400K to Seek New Therapies for Childhood AML

News

Kimberly Stegmaier, MD, of the Dana-Farber Cancer Institute, has been awarded a $400,000 research grant to continue her work to find new treatments for pediatric acute myeloid leukemia (AML) — ... Read more

November 16, 2020November 16, 2020

US Trial Testing Mylotarg Plus Venclexta for AML Now Enrolling Participants

News

A Phase 1b study testing Mylotarg (gemtuzumab ozogamicin) plus Venclexta (venetoclax) for adults with relapsing or refractory acute myeloid leukemia (AML) is currently enrolling patients. The trial (NCT04070768) is taking place across four clinical sites ... Read more

November 12, 2020November 12, 2020

FDA Grants Orphan Drug Designation to Immune-Onc’s IO-202

News

The U.S. Food and Drug Administration (FDA) has given the designation of orphan drug to Immune-Onc Therapeutics’ investigational antibody-based therapy IO-202 for the treatment of acute myeloid leukemia (AML). Orphan ... Read more

November 9, 2020November 9, 2020

1st Patient Dosed in Phase 1/2 Trial Testing CAR T-cell Therapy MB-102 in AML

News

The first patient has been dosed in an open-label Phase 1/2 clinical trial evaluating the safety and efficacy of MB-102 — a CD123-targeted CAR T-cell therapy — in adults with ... Read more

November 5, 2020November 5, 2020

Complete Remission Reported in Patient in Ongoing Trial of APVO436

News

Aptevo Therapeutics’ investigational therapy APVO436 resulted in a patient’s complete disease remission in an ongoing trial in people with relapsed or refractory acute myeloid leukemia (AML) and high-grade myelodysplastic syndrome (MDS), the company announced. ... Read more

October 29, 2020October 29, 2020

Dosing Begins in Phase 1 Trial Testing PRT1419 for Advanced AML, Other Blood Cancers

News

The first patient has been dosed in a Phase 1 trial testing the investigational cancer therapy PRT1419 in patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML), Prelude ... Read more

October 22, 2020October 22, 2020

FDA Approves Venclexta Combinations for Newly Diagnosed AML

News

The U.S. Food and Drug Administration (FDA) has granted full approval to Venclexta (venetoclax), in combination with Vidaza (azacitidine), Dacogen (decitabine), or low-dose cytarabine, for treating newly diagnosed adults with ... Read more

October 19, 2020October 19, 2020

Telehealth ‘Helpful’ Alternative to In-person Care, Rare Disease Patients Say

News, syndicated

A majority of rare disease patients using telehealth during the COVID-19 pandemic thought the experience positive, and many would like the option of continuing its use in future appointments, a series ... Read more

October 15, 2020October 15, 2020

Omidubicel Shows Further Trial Benefits for Marrow Transplants in AML, Other Cancers

News

Omidubicel, an experimental cell therapy for blood cancer patients needing a bone marrow transplant, is superior to standard umbilical cord blood transplant at increasing the proportion of patients achieving normal platelet counts within ... Read more

October 12, 2020October 12, 2020

TXNIP Protein Deficiency Linked to Poor Prognosis for AML Patients, Study Finds

News

Low expression levels of the protein TXNIP — thioredoxin interacting protein — was associated with worse outcomes in people with acute myeloid leukemia (AML), according to the results of a ... Read more